Tecan Enhances Specialty Diagnostics Portfolio With ELISA Kit Asset Acquisition
Tecan Group (SIX Swiss Exchange: TECN) has announced a strategic agreement to acquire key ELISA immunoassay assets from Cisbio Bioassays SAS, a subsidiary of the global life sciences and diagnostics company, Revvity Inc. This acquisition encompasses the manufacturing processes of four ELISA kits, two of which are in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, while the other two are designated for research use only (RUO).
To maintain uninterrupted supply and availability of these critical ELISA kits during the transition period, IBL International GmbH, a Tecan company, has entered into a Master Distributorship Agreement with Cisbio Bioassays. This agreement allows IBL to resell the kits until the asset transfer is finalized. IBL, renowned for its expertise in specialty diagnostics, will assume full responsibility for manufacturing, distribution, and regulatory compliance once the asset transition is complete.
The ELISA kits included in the acquisition are:
- CGA-ELISA-NG (Chromogranin A New Generation ELISA)* – CE IVD certified: Used for diagnosing neuroendocrine tumors in adult patients by determining the presence and progression of the disease.
- P3NP-ELISA (N-Terminal Procollagen III Peptide ELISA)* – CE IVD certified: Measures PIIINP levels in serum, EDTA, or Heparin plasma to assess collagen III synthesis and monitor the risk of liver fibrosis in psoriasis patients undergoing methotrexate treatment.
- CGA-EL-US-NG RUO* and P3NP-EL-US RUO* – Research use only ELISA kits that support further scientific advancements in biomedical research.
By integrating these ELISA products into its portfolio, Tecan aims to ensure their continued availability while upholding the highest standards of quality and regulatory compliance. The acquisition reinforces Tecan’s commitment to offering innovative solutions in specialty diagnostics and enhancing its role as a key provider of diagnostic and research tools.
Mukta Acharya, Head of Tecan’s Life Sciences Business, emphasized the significance of the acquisition, stating: “This strategic purchase aligns with our commitment to supporting customers with high-quality solutions while strengthening our portfolio in specialty diagnostics. As regulatory requirements continue to evolve, we are proactively expanding our offering to ensure laboratories have access to reliable, compliant solutions that meet their needs today and in the future. Tecan and Cisbio have a long-standing collaboration in the IVD sector. The transition of these important ELISA kits marks a strategic step to expand the IBL specialty diagnostics portfolio under IVDR.”
The decision to acquire these assets is driven by Tecan’s goal of bolstering its specialty diagnostics business, ensuring customers receive uninterrupted access to advanced diagnostic tools. The CGA-ELISA-NG and P3NP-ELISA kits, in particular, play a critical role in clinical diagnostics, aiding physicians in the detection and monitoring of neuroendocrine tumors and liver fibrosis, respectively. Meanwhile, the research-use-only kits will continue to support ongoing advancements in biomedical research, enabling scientists to develop new insights into disease mechanisms and potential therapies.
By bringing the production and distribution of these ELISA kits in-house, Tecan further strengthens its capabilities in manufacturing precision diagnostics. IBL International GmbH’s expertise in specialty diagnostics ensures that these assays will continue to meet stringent regulatory requirements while maintaining consistency in quality and reliability. The integration of these ELISA kits also aligns with the ongoing implementation of the In Vitro Diagnostic Regulation (IVDR) in Europe, which places greater emphasis on stringent regulatory oversight and quality standards for diagnostic products.
Tecan’s move to acquire these assets reflects a broader industry trend toward consolidation and portfolio diversification in the diagnostic sector. As personalized medicine and targeted diagnostics gain prominence, companies are seeking to expand their offerings to cater to evolving clinical and research demands. The acquisition not only secures Tecan’s position in the specialty diagnostics market but also provides a competitive edge by offering a more comprehensive suite of diagnostic solutions.
The transaction underscores Tecan’s proactive approach to addressing industry challenges, such as evolving regulatory landscapes and increasing demand for high-precision diagnostic tools. By securing these ELISA kits, Tecan ensures that laboratories and researchers worldwide continue to have access to trusted and validated diagnostic solutions.
Tecan plans to leverage its expertise in life sciences and automation to further enhance these ELISA assays. The company’s strong presence in laboratory automation and diagnostics positions it well to integrate these assays into broader diagnostic workflows, improving efficiency and accuracy for end users. Additionally, the acquisition sets the stage for potential future expansions in the specialty diagnostics space, as Tecan continues to explore new opportunities for growth and innovation.
With this acquisition, Tecan reaffirms its commitment to excellence in diagnostic and research solutions, ensuring that laboratories and healthcare providers have access to reliable and high-quality ELISA assays for years to come.
